Browse by UCL people
Group by: Type | Date
Number of items: 12.
2023
Genoud, Vassilis;
Kinnersley, Ben;
Brown, Nicholas F;
Ottaviani, Diego;
Mulholland, Paul;
(2023)
Therapeutic Targeting of Glioblastoma and the Interactions with Its Microenvironment.
Cancers
, 15
(24)
, Article 5790. 10.3390/cancers15245790.
|
2021
|
Carter, TJ;
Agliardi, G;
Lin, F-Y;
Ellis, M;
Jones, C;
Robson, M;
Richard-Londt, A;
... Chester, K; + view all
(2021)
Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation.
Small
, Article e2005241. 10.1002/smll.202005241.
(In press).
|
 |
2018
|
Abdollah, MRA;
Carter, TJ;
Jones, C;
Kalber, TL;
Rajkumar, V;
Tolner, B;
Gruettner, C;
... Chester, KA; + view all
(2018)
Fucoidan Prolongs the Circulation Time of Dextran-Coated Iron Oxide Nanoparticles.
ACS Nano
, 12
(2)
pp. 1156-1169.
10.1021/acsnano.7b06734.
|
|
Brown, NF;
Carter, TJ;
Ottaviani, D;
Mulholland, P;
(2018)
Harnessing the immune system in glioblastoma.
British Journal of Cancer
, 119
(10)
pp. 1171-1181.
10.1038/s41416-018-0258-8.
|
|
|
Brown, NF;
Williams, M;
Arkenau, H-T;
Fleming, RA;
Tolson, J;
Yan, L;
Zhang, J;
... Mulholland, P; + view all
(2018)
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [¹¹C]GSK2256098.
Neuro-Oncology
, 20
(12)
pp. 1634-1642.
10.1093/neuonc/noy078.
|
2017
|
Brown, N;
Carter, T;
Mulholland, P;
(2017)
Adjuvant Chemotherapy is Indicated in Patients with Lower Grade Glioma.
Clinical Oncology
, 29
(3)
pp. 141-142.
10.1016/j.clon.2016.11.006.
|
|
Brown, NF;
Carter, T;
Kitchen, N;
Mulholland, P;
(2017)
Dabrafenib and trametinib in BRAFV600E mutated glioma.
CNS Oncology
, 6
(4)
10.2217/cns-2017-0006.
|
|
|
Brown, NF;
Carter, T;
Mulholland, P;
(2017)
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
CNS Oncology
, 6
(1)
10.2217/cns-2016-0031.
|
|
2016
|
Brown, N;
McBain, C;
Nash, S;
Hopkins, K;
Sanghera, P;
Saran, F;
Phillips, M;
... Mulholland, P; + view all
(2016)
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
PLoS ONE
, 11
(5)
10.1371/journal.pone.0156369.
|
|
Carter, T;
Mulholland, P;
Chester, K;
(2016)
Antibody-targeted nanoparticles for cancer treatment.
Immunotherapy
, 8
(8)
pp. 941-958.
10.2217/imt.16.11.
|
|
Carter, T;
Shawy, H;
Cohn-Brown, D;
Chester, K;
Mulholland, P;
(2016)
Ipilimumab and Bevacizumab in Glioblastoma.
Clinical Oncology
, 28
(10)
pp. 622-626.
10.1016/j.clon.2016.04.042.
|
|
|
Tudzarova, S;
Mulholland, P;
Dey, A;
Stoeber, K;
Okorokov, AL;
Williams, GH;
(2016)
p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.
Cell Cycle
, 15
(21)
pp. 2958-2972.
10.1080/15384101.2016.1231281.
|
